Tango Therapeutics, Inc.
TNGX
Rangering i aksjer
#4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aksjekurs
$27.18
Sist synkronisert: 2026-07-31
Markedsverdi
$3.38B
Endring (1 dag)
-1.41%
Endring (1 år)
202.34%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Kategori
Healthcare
Historikk for aksjesplitt for Tango Therapeutics, Inc. (TNGX)
Aksjen Tango Therapeutics, Inc. (symbol: TNGX) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én TNGX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 TNGX-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én TNGX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 TNGX-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
